Skip to content

Study · Randomized controlled trial · n = 12 · 2005

5 results

Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.

Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW

Clinical pharmacology and therapeutics1 Jul 2005Cited by 48 (Europe PMC)

PMID16003295 (opens in a new tab)DOI10.1016/j.clpt.2005.04.003 (opens in a new tab)PepBankPUB-16003295
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In patients with acromegaly, octreotide clearance was 15.8 L/h versus 8.0 L/h for SOM230.

    In plain wordsIn patients with acromegaly, octreotide clearance was higher than SOM230 clearance.

    Peptide
    Octreotide
    Outcome
    IncreaseApparent clearance
    Study

    n = 12

    Comparator
    SOM230
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Apparent clearance
    15.8 L/h
    octreotide 100 microg
    Apparent clearance
    8 L/h
    SOM230

    Source sentences

    Summary
    The apparent clearance for SOM230 is approximately half of that for octreotide (8.0 L/h versus 15.8 L/h).
    1 context sentence
    Summary · context
    In a double-blind, 3-period, crossover, proof-of-concept study, 12 patients with active acromegaly were randomized to single subcutaneous doses of SOM230 (100 and 250 microg) and octreotide (100 microg).
  2. 02HumanRandomized controlled trialPharmacokinetics

    In patients with acromegaly, octreotide half-life was 2.3 hours versus 11.8 hours for SOM230.

    In plain wordsIn patients with acromegaly, octreotide had a shorter half-life than SOM230.

    Peptide
    Octreotide
    Outcome
    DecreaseElimination half-life
    Study

    n = 12

    Comparator
    SOM230
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Elimination half-life
    2.3 hours
    octreotide 100 microg
    Elimination half-life
    11.8 hours
    SOM230

    Source sentences

    Summary
    The elimination half-life for SOM230 is about 5 times longer than that for octreotide (11.8 hours versus 2.3 hours).
    1 context sentence
    Summary · context
    In a double-blind, 3-period, crossover, proof-of-concept study, 12 patients with active acromegaly were randomized to single subcutaneous doses of SOM230 (100 and 250 microg) and octreotide (100 microg).
  3. 03HumanRandomized controlled trialActivity measurement

    In patients with acromegaly, GH inhibition EC50 was 46 pg/mL for octreotide versus 553 pg/mL for SOM230.

    In plain wordsIn patients with acromegaly, octreotide had a lower concentration for half-maximal growth hormone inhibition than SOM230.

    Peptide
    Octreotide
    Outcome
    DecreaseGH inhibition EC50
    Study

    n = 12

    Comparator
    SOM230
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    EC50
    46 pg/mL
    octreotide
    EC50
    553 pg/mL
    SOM230

    Source sentences

    Summary
    The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.
    1 context sentence
    Summary · context
    In a double-blind, 3-period, crossover, proof-of-concept study, 12 patients with active acromegaly were randomized to single subcutaneous doses of SOM230 (100 and 250 microg) and octreotide (100 microg).
  4. 04HumanRandomized controlled trialPharmacokinetics

    In patients with acromegaly, EC50 coefficients of variation were 164% for octreotide and 65% for SOM230.

    In plain wordsIn patients with acromegaly, octreotide showed greater between-patient EC50 variability than SOM230.

    Peptide
    Octreotide
    Outcome
    IncreaseEC50 interpatient variability
    Study

    n = 12

    Comparator
    SOM230
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    EC50 coefficient of variation
    164%
    octreotide
    EC50 coefficient of variation
    65%
    SOM230

    Source sentences

    Summary
    The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.
    1 context sentence
    Summary · context
    In a double-blind, 3-period, crossover, proof-of-concept study, 12 patients with active acromegaly were randomized to single subcutaneous doses of SOM230 (100 and 250 microg) and octreotide (100 microg).
  5. 05HumanObservational studyMechanism

    In patients with acromegaly, a direct inhibitory model described the relationship between octreotide concentrations and GH levels.

    In plain wordsIn patients with acromegaly, an inhibitory model described the relationship between octreotide concentrations and growth hormone.

    Peptide
    Octreotide
    Outcome
    Not applicableGH concentration-response relationship
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The relationship between GH levels and plasma concentrations of SOM230 and octreotide is well described by a direct inhibitory model.
    1 context sentence
    Summary · context
    In a double-blind, 3-period, crossover, proof-of-concept study, 12 patients with active acromegaly were randomized to single subcutaneous doses of SOM230 (100 and 250 microg) and octreotide (100 microg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.